Clinical Trials in New York State

Showing 3461-3480 of 17,167 trials

Access Cannulation Trial II

NCT05490225

This is a pivotal, interventional, prospective, single-arm, open-label, multi-site clinical investigation intended to support FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.

Dialysis; ComplicationsVascular Access Complication

Voyager Biomedical100 participantsStarted Apr 2025

Dothan, Alabama, United States • Riverside, California, United States • Boston, Massachusetts, United States +5 more locations

Active Not RecruitingPhase 279 miles

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

NCT06116890

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Neovascular Age-Related Macular Degeneration (nAMD)

Kyowa Kirin Co., Ltd.180 participantsStarted Jan 2024

Mesa, Arizona, United States • Tucson, Arizona, United States • Arcadia, California, United States +81 more locations

Access Cannulation Trial II

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Find Trials by Condition in New York State

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

OCS Heart Perfusion Post-Approval Registry

Stress Hydrocortisone In Pediatric Septic Shock

Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention

Individualizing Treatment for Asthma in Primary Care (Full Study)

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Clinical Validation Study of the Eximis CS (Contained Segmentation) System

Using Re-inforcement Learning to Automatically Adapt a Remote Therapy Intervention (RTI) for Reducing Adolescent Violence Involvement

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Multisite RCT of STEP-Home: A Transdiagnostic Skill-based Community Reintegration Workshop

Empowering Young Parents: Building Healthy Relationships Study

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC